Abstract | OBJECTIVE:
Amiodarone is a highly effective antiarrhythmic therapy, however its toxicity profile often limits treatment. This is particularly relevant in adults with congenital heart disease (CHD), who are often young and in whom other antiarrhythmic agents commonly fail or are contraindicated. We sought to determine incidence and predictors of adverse effects caused by amiodarone in adult CHD (ACHD). DESIGN: A retrospective review of patients with moderate to complex ACHD treated with amiodarone at our center between 2000 and 2017 was performed. Incidence and predictors of adverse effects were described. Efficacy of amiodarone therapy in controlling the clinical arrhythmia was assessed as complete, partial, or failed. RESULTS: CONCLUSIONS:
Amiodarone therapy is effective in moderate to complex ACHD patients, but is frequently limited by adverse effects. ACHD patients seem especially vulnerable to thyroid dysfunction, with Fontan patients in particular at increased risk of AIT.
|
Authors | Benjamin M Moore, Rachael L Cordina, Mark A McGuire, David S Celermajer |
Journal | Congenital heart disease
(Congenit Heart Dis)
Vol. 13
Issue 6
Pg. 944-951
(Nov 2018)
ISSN: 1747-0803 [Electronic] United States |
PMID | 30239160
(Publication Type: Journal Article)
|
Copyright | © 2018 Wiley Periodicals, Inc. |
Chemical References |
- Anti-Arrhythmia Agents
- Amiodarone
|
Topics |
- Adolescent
- Adult
- Aged
- Amiodarone
(adverse effects)
- Anti-Arrhythmia Agents
(adverse effects)
- Arrhythmias, Cardiac
(complications, drug therapy)
- Comorbidity
- Drug-Related Side Effects and Adverse Reactions
(epidemiology)
- Female
- Follow-Up Studies
- Heart Defects, Congenital
(complications)
- Humans
- Male
- Middle Aged
- New South Wales
(epidemiology)
- Retrospective Studies
- Risk Assessment
- Young Adult
|